Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome

meta-analysis of randomized trials

Pedro A. Villablanca, David Holmes, Divyanshu Mohananey, David F. Briceno, Ivan J. Núñez Gil, Faraj Kargoli, Tanush Gupta, Jorge Kizer, Anna Bortnick, Jose M. Wiley, Mark A. Menegus, Robert Pyo, Mario J. Garcia, Harish Ramakrishna, Farouk Mookadam

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: We carried out a meta-analysis summarizing the efficacy and safety of direct factor Xa inhibitor (DXI) in patients receiving guideline-based antiplatelet therapy (GBAT) after an acute coronary syndrome. BACKGROUND: Randomized-controlled trials have shown that the addition of a DXI to GBAT after acute coronary syndrome can reduce ischemic events, the trade-off being an increase in major bleeding complications. METHODS: PubMed, Central, Embase, The Cochrane Register, Google Scholar databases, and the scientific session abstracts were searched for eligible randomized trials from 1 January 1990 through 31 December 2016. RESULTS: Nine randomized-controlled trials were included in this meta-analysis enrolling a total of 45651 patients. There was a significant reduction in major adverse cardiovascular events with DXIs/GBAT compared with GBAT alone [odds ratio (OR): 0.88; 95% confidence interval (CI): 0.82–0.94, number needed to treat=52]. There were also significant reductions in two individual components of major adverse cardiovascular events: myocardial infarction (OR: 0.89; 95% CI: 0.81–0.98) and stent thrombosis (OR: 0.73; 95% CI: 0.59–0.90), favoring the DXI/GBAT group. There was an increased risk of major bleeding (OR: 2.51; 95% CI: 1.82–3.46) and intracranial hemorrhage (OR: 3.47; 95% CI: 1.76–6.86) compared with GBAT. CONCLUSION: In acute coronary syndromes, the addition of a DXI to GBAT results in a significant reduction of major adverse cardiovascular events, myocardial infarction, and stent thrombosis, offset by an increased risk of bleeding.

Original languageEnglish (US)
JournalCoronary Artery Disease
DOIs
StateAccepted/In press - Mar 21 2017

Fingerprint

Acute Coronary Syndrome
Meta-Analysis
Guidelines
Odds Ratio
Confidence Intervals
Hemorrhage
Therapeutics
Stents
Thrombosis
Randomized Controlled Trials
Myocardial Infarction
Numbers Needed To Treat
Intracranial Hemorrhages
Group Psychotherapy
PubMed
Databases
Safety
Factor Xa Inhibitors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Villablanca, P. A., Holmes, D., Mohananey, D., Briceno, D. F., Núñez Gil, I. J., Kargoli, F., ... Mookadam, F. (Accepted/In press). Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials. Coronary Artery Disease. https://doi.org/10.1097/MCA.0000000000000485

Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome : meta-analysis of randomized trials. / Villablanca, Pedro A.; Holmes, David; Mohananey, Divyanshu; Briceno, David F.; Núñez Gil, Ivan J.; Kargoli, Faraj; Gupta, Tanush; Kizer, Jorge; Bortnick, Anna; Wiley, Jose M.; Menegus, Mark A.; Pyo, Robert; Garcia, Mario J.; Ramakrishna, Harish; Mookadam, Farouk.

In: Coronary Artery Disease, 21.03.2017.

Research output: Contribution to journalArticle

Villablanca, Pedro A. ; Holmes, David ; Mohananey, Divyanshu ; Briceno, David F. ; Núñez Gil, Ivan J. ; Kargoli, Faraj ; Gupta, Tanush ; Kizer, Jorge ; Bortnick, Anna ; Wiley, Jose M. ; Menegus, Mark A. ; Pyo, Robert ; Garcia, Mario J. ; Ramakrishna, Harish ; Mookadam, Farouk. / Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome : meta-analysis of randomized trials. In: Coronary Artery Disease. 2017.
@article{9a2a77ad677e4e38af3797088c473083,
title = "Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials",
abstract = "OBJECTIVE: We carried out a meta-analysis summarizing the efficacy and safety of direct factor Xa inhibitor (DXI) in patients receiving guideline-based antiplatelet therapy (GBAT) after an acute coronary syndrome. BACKGROUND: Randomized-controlled trials have shown that the addition of a DXI to GBAT after acute coronary syndrome can reduce ischemic events, the trade-off being an increase in major bleeding complications. METHODS: PubMed, Central, Embase, The Cochrane Register, Google Scholar databases, and the scientific session abstracts were searched for eligible randomized trials from 1 January 1990 through 31 December 2016. RESULTS: Nine randomized-controlled trials were included in this meta-analysis enrolling a total of 45651 patients. There was a significant reduction in major adverse cardiovascular events with DXIs/GBAT compared with GBAT alone [odds ratio (OR): 0.88; 95{\%} confidence interval (CI): 0.82–0.94, number needed to treat=52]. There were also significant reductions in two individual components of major adverse cardiovascular events: myocardial infarction (OR: 0.89; 95{\%} CI: 0.81–0.98) and stent thrombosis (OR: 0.73; 95{\%} CI: 0.59–0.90), favoring the DXI/GBAT group. There was an increased risk of major bleeding (OR: 2.51; 95{\%} CI: 1.82–3.46) and intracranial hemorrhage (OR: 3.47; 95{\%} CI: 1.76–6.86) compared with GBAT. CONCLUSION: In acute coronary syndromes, the addition of a DXI to GBAT results in a significant reduction of major adverse cardiovascular events, myocardial infarction, and stent thrombosis, offset by an increased risk of bleeding.",
author = "Villablanca, {Pedro A.} and David Holmes and Divyanshu Mohananey and Briceno, {David F.} and {N{\'u}{\~n}ez Gil}, {Ivan J.} and Faraj Kargoli and Tanush Gupta and Jorge Kizer and Anna Bortnick and Wiley, {Jose M.} and Menegus, {Mark A.} and Robert Pyo and Garcia, {Mario J.} and Harish Ramakrishna and Farouk Mookadam",
year = "2017",
month = "3",
day = "21",
doi = "10.1097/MCA.0000000000000485",
language = "English (US)",
journal = "Coronary Artery Disease",
issn = "0954-6928",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome

T2 - meta-analysis of randomized trials

AU - Villablanca, Pedro A.

AU - Holmes, David

AU - Mohananey, Divyanshu

AU - Briceno, David F.

AU - Núñez Gil, Ivan J.

AU - Kargoli, Faraj

AU - Gupta, Tanush

AU - Kizer, Jorge

AU - Bortnick, Anna

AU - Wiley, Jose M.

AU - Menegus, Mark A.

AU - Pyo, Robert

AU - Garcia, Mario J.

AU - Ramakrishna, Harish

AU - Mookadam, Farouk

PY - 2017/3/21

Y1 - 2017/3/21

N2 - OBJECTIVE: We carried out a meta-analysis summarizing the efficacy and safety of direct factor Xa inhibitor (DXI) in patients receiving guideline-based antiplatelet therapy (GBAT) after an acute coronary syndrome. BACKGROUND: Randomized-controlled trials have shown that the addition of a DXI to GBAT after acute coronary syndrome can reduce ischemic events, the trade-off being an increase in major bleeding complications. METHODS: PubMed, Central, Embase, The Cochrane Register, Google Scholar databases, and the scientific session abstracts were searched for eligible randomized trials from 1 January 1990 through 31 December 2016. RESULTS: Nine randomized-controlled trials were included in this meta-analysis enrolling a total of 45651 patients. There was a significant reduction in major adverse cardiovascular events with DXIs/GBAT compared with GBAT alone [odds ratio (OR): 0.88; 95% confidence interval (CI): 0.82–0.94, number needed to treat=52]. There were also significant reductions in two individual components of major adverse cardiovascular events: myocardial infarction (OR: 0.89; 95% CI: 0.81–0.98) and stent thrombosis (OR: 0.73; 95% CI: 0.59–0.90), favoring the DXI/GBAT group. There was an increased risk of major bleeding (OR: 2.51; 95% CI: 1.82–3.46) and intracranial hemorrhage (OR: 3.47; 95% CI: 1.76–6.86) compared with GBAT. CONCLUSION: In acute coronary syndromes, the addition of a DXI to GBAT results in a significant reduction of major adverse cardiovascular events, myocardial infarction, and stent thrombosis, offset by an increased risk of bleeding.

AB - OBJECTIVE: We carried out a meta-analysis summarizing the efficacy and safety of direct factor Xa inhibitor (DXI) in patients receiving guideline-based antiplatelet therapy (GBAT) after an acute coronary syndrome. BACKGROUND: Randomized-controlled trials have shown that the addition of a DXI to GBAT after acute coronary syndrome can reduce ischemic events, the trade-off being an increase in major bleeding complications. METHODS: PubMed, Central, Embase, The Cochrane Register, Google Scholar databases, and the scientific session abstracts were searched for eligible randomized trials from 1 January 1990 through 31 December 2016. RESULTS: Nine randomized-controlled trials were included in this meta-analysis enrolling a total of 45651 patients. There was a significant reduction in major adverse cardiovascular events with DXIs/GBAT compared with GBAT alone [odds ratio (OR): 0.88; 95% confidence interval (CI): 0.82–0.94, number needed to treat=52]. There were also significant reductions in two individual components of major adverse cardiovascular events: myocardial infarction (OR: 0.89; 95% CI: 0.81–0.98) and stent thrombosis (OR: 0.73; 95% CI: 0.59–0.90), favoring the DXI/GBAT group. There was an increased risk of major bleeding (OR: 2.51; 95% CI: 1.82–3.46) and intracranial hemorrhage (OR: 3.47; 95% CI: 1.76–6.86) compared with GBAT. CONCLUSION: In acute coronary syndromes, the addition of a DXI to GBAT results in a significant reduction of major adverse cardiovascular events, myocardial infarction, and stent thrombosis, offset by an increased risk of bleeding.

UR - http://www.scopus.com/inward/record.url?scp=85015968992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015968992&partnerID=8YFLogxK

U2 - 10.1097/MCA.0000000000000485

DO - 10.1097/MCA.0000000000000485

M3 - Article

JO - Coronary Artery Disease

JF - Coronary Artery Disease

SN - 0954-6928

ER -